TOKYO -- Fujifilm Holdings' flu-fighting drug Avigan failed to prove sustained clinical recovery from COVID-19 in a test conducted by a Canadian partner in the U.S., Mexico and Brazil, significantly hampering its chances of implication in the American market.
Coronavirus
Avigan fails to prove COVID efficacy in U.S. trials, in blow to Fujifilm
Company will continue efforts in Japan, but path to American market looks closed
Fujifilm and its partner had hoped to request emergency use authorization of Avigan as a COVID-19 treatment as early as this year.
Read Next
Latest on Coronavirus
